Identifying genetic factors affecting ADHD treatment response
Pharmacogenomics of Stimulant Treatment Response in Children and Adolescents With Attention-Deficit/ Hyperactivity Disorder
This study is trying to find out if certain genes affect how well kids and young adults with ADHD respond to a common medication called methylphenidate.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 6 Years to 24 Years |
| Sex | All |
| Sponsor | University of Calgary Academic / other |
| Locations | 1 site (Calgary, Alberta) |
| Trial ID | NCT06221358 on ClinicalTrials.gov |
What this trial studies
The Pharmacogenomics of Stimulant Treatment Response study aims to uncover genetic profiles that influence how children and adolescents respond to methylphenidate, a common medication for ADHD. By focusing on individuals aged 6 to 24, the study seeks to establish a connection between genetic markers and treatment outcomes, which could lead to more personalized and effective ADHD management. The research will also create a platform for discovering additional genetic and non-genetic factors that impact mental health treatment in young patients.
Who should consider this trial
Good fit: Ideal candidates are children and adolescents aged 6 to 24 with a primary diagnosis of ADHD who are starting treatment with methylphenidate.
Not a fit: Patients with co-occurring severe mental health disorders or those with specific medical histories may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more tailored ADHD treatments, improving efficacy and reducing side effects for patients.
How similar studies have performed: While pharmacogenomic approaches in other areas of psychiatry have shown promise, this specific focus on ADHD treatment response is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients will be eligible for participation if all the following are true. * Aged 6 - 24 years. * Located in Western Canada (i.e., Alberta, British Columbia, Saskatchewan, Manitoba). * Primary diagnosis of ADHD (all types). * Starting Methylphenidate (excluding immediate release forms) treatment. Exclusion Criteria: Patients will be excluded from participation if any of the following are true. * Co-occurring psychotic, bipolar or eating disorders. * Significant risk of suicide. * An intellectual disability, or diagnosis of autism spectrum disorder (ASD) or tics/Tourette disorders. * Past 12-month high-risk alcohol or substance use defined as monthly or more frequent use. * Psychotherapy or brain stimulation-based therapy initiated within 8 weeks of referral or plans to initiate/change these types of therapies during the study * History of liver or bone marrow (hematopoietic cell) transplant as these events can result in ambiguous genomic results.
Where this trial is running
Calgary, Alberta
- University of Calgary — Calgary, Alberta, Canada (Recruiting)
Study contacts
- Principal investigator: Chad Bousman, MPH, PhD — University of Calgary
- Study coordinator: Weng-Sam Siu, MSPT, MSc
- Email: sam.siu@ucalgary.ca
- Phone: 5875739747
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.